NEW YORK, Oct. 6, 2016 /PRNewswire/ -- Pomerantz LLP is
investigating claims on behalf of investors of Mylan N.V. ("Mylan"
or the "Company") (NASDAQ: MYL) (ISIN: NL0011031208). Investors are
advised to contact Robert S.
Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
9980.
The investigation concerns whether Mylan and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
[Click here to join a class action]
On October 5, 2016, the Centers
for Medicare and Medicaid Services ("CMS") issued a letter stating
that Mylan had for years overcharged the U.S. Medicaid health
program to buy its EpiPen shot, despite being told that the Company
needed to provide bigger discounts under the law. The CMS
letter stated that from 2011 to 2015, the U.S. Medicaid health
program spent approximately $797
million on EpiPens, including rebates of roughly 13%, rather
than the discount of 23.1% that the U.S. should have
received. The letter stated that the government has
previously "expressly told Mylan that the [EpiPen] product is
incorrectly classified."
On this news, Mylan's share price has fallen as much as
$1.18, or 3.1%, to $36.85 during intraday trading on October 6, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los
Angeles, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz Firm pioneered the field of securities class actions.
Today, more than 80 years later, the Pomerantz Firm continues in
the tradition he established, fighting for the rights of the
victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of class members. See
www.pomerantzlaw.com
CONTACT:
Robert S.
Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mylan-nv--myl-300340693.html
SOURCE Pomerantz LLP